Immunohistochemical expression profile and prognosis in patients with diffuse large B-cell lymphoma with or without human immunodeficiency virus infection

References

• Lossos IS, Morgensztern D. Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol 2006;24:995–1007.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Weng AP, et al Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Lossos IS, Jones CD, Warnke R, et al Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2002;98:945–951.
   Web of Science ®Google Scholar
• Lossos IS, Czerwinski DK, Alizadeh AA, et al Prediction of survival in diffuse large B-cell expression of six genes. N Engl J Med 2004;350:1828–1837.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Lossos IS, Levy R. Molecular outcome prediction in diffuse large-B cell lymphoma. N Engl J Med 2009;360:2794–2795.
   PubMed Web of Science ®Google Scholar
• Dunphy CH. Gene expression profiling data in lymphoma and leukaemia. Arch Pathol Lab Med 2006;130:483–520.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al The use of molecular profiling to predict survival after chemotherapy for diffuse large- B cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Jong D, Rosenwald A, Chhanabhai M, et al Immunohistochemical prognostic markers in diffuse-large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications - a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007;25:805–812.
   PubMed Web of Science ®Google Scholar
• De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia 2007;21:37–43.
   PubMed Web of Science ®Google Scholar
• Barrans SL, Carter I, Owen RG, et al Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002;99:1136–1143.
   PubMed Web of Science ®Google Scholar
• Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006;130:1819–1824.
   PubMed Web of Science ®Google Scholar
• Alacacioglu I, Ozcan MA, Ozkal S, et al Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. Hematology 2009;14:84–89.
   PubMed Web of Science ®Google Scholar
• Al-Kuraya KS, Siraj AK, Al-Dayel FA, et al Epigenetic changes and their clinical relevance in Saudi diffuse large B-cell lymphoma. A molecular and tissue microarray analysis of 100 cases. Saudi Med J 2005;26:1099–1103.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Dirnhofer S, Sabattini E, et al Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica 2005;90:341–347.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gaidano G, Gloghini A, et al Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin's lymphomas. Blood 1998;91:747–755.
   PubMed Web of Science ®Google Scholar
• Chang CC, McClintock S, Cleveland RP, et al Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse-large B-cell lymphoma. Am J Surg Pathol 2004;28:464–470.
   PubMed Web of Science ®Google Scholar
• Hans CP, Wesenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Colomo L, López-Guillermo A, Perales M, et al Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003;101:78–84.
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Dimhofer S, Sabattini E, et al Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumours with nodal presentation on tissue microarrays. Haematologica 2005;90:341–347.
   PubMed Web of Science ®Google Scholar
• Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000;14:1675–1688.
   PubMed Web of Science ®Google Scholar
• Kirk O, Pedersen C, Cozzi-Lepri A, et al EuroSIDA Study Group. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406–3412.
   PubMed Web of Science ®Google Scholar
• Carbone A. AIDS-related non-Hodgkin's subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97:744–751.
   PubMed Web of Science ®Google Scholar
• Carbone A, Dolcetti R, Gloghini A. Immunophenotypic and molecular analyses of acquired immune deficiency syndrome-related and Epstein-Barr virus-associated lymphomas: a comparative study. Hum Pathol 1996;27:133–146.
   PubMed Web of Science ®Google Scholar
• Carbone A, Gloghini A, Larocca LM, et al Expression profile of MUM/IFR4, BCL-6 and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood 2001;97: 744–751.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(RR-17):1–18.
   Google Scholar
• Miralles P, Rubio C, Berenguer J, et al Recomendaciones de GESIDA/Plan Nacional sobre el Sida sobre el diagnóstico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc) 2002;118:225–236.
   PubMedGoogle Scholar
• Harris NL, Jaffe ES, Diebold J, et al The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. J Clin Oncol 1999;17:3835–3849.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al Revised response criteria for malignant lymphoma. The International Harmonization Project on Lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Peto R, Pike MC. Conservatism of the approximation Σ(O-E)2/E in the log-rank test for survival data or tumor incidence data. Biometrics 1973;29:579–584.
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models and life tables. J R Stat Soc 1972;3:187–200.
   Google Scholar
• Barrans SL, Fenton JA, Banham A, Owen RG, Jack AS. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 2004;104:2933–2935.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Neppalli VT, Wright G, et al BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. Clin Oncol 2006;24: 961–968.
   Web of Science ®Google Scholar
• Linderoth J, Ehinger M, Akerman M, et al Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. Eur J Haematol 2007;79:146–149.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Went P, Zimpfer A, et al Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer 2005;5:162.
   PubMed Web of Science ®Google Scholar
• Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol 2005;32:227–234.
   PubMed Web of Science ®Google Scholar
• Ramuz O, Bouabdallah R, Devilard E, et al Identification of TCL1A as an immunohistochemical marker of adverse outcome in diffuse large B-cell lymphomas. Int J Oncol 2005;26:151–157.
   PubMed Web of Science ®Google Scholar
• Went P, Dellas T, Bourgau C, et al Expression profile and prognostic significance of CD24, p53 and p21 in lymphomas. A tissue microarray study of over 600 non-Hodgkin lymphomas. Dtsch Med Wochenschr 2004;129:2094–2099.
   PubMed Web of Science ®Google Scholar
• Tzankov A, Pehrs AC, Zimpfer A, et al Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747–752.
   PubMed Web of Science ®Google Scholar
• Lee NR, Song EK, Jang KY, et al Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis. Leuk Lymphoma 2008;49:247–256.
   PubMed Web of Science ®Google Scholar
• Van Imhoff GW, Boerma EJ, van der Holt B, et al Prognostic impact of germinal-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol 2006;24:4135–4142.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, et al Influence of highly active antiretroviral therapy (HAART) on response to treatment and survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. Br J Haematol 2001;112:909–915.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, et al Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15:1483–1491.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, et al Favorable impact of virological response to HAART on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002;43:1837–1842.
   PubMed Web of Science ®Google Scholar
• Ilić I, Mitrović Z, Aurer I, et al Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol 2009;90:74–80.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, et al Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842–1847.
   PubMed Web of Science ®Google Scholar
• Wilson KS, Sehn LH, Berry B, et al CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma. Leuk Lymphoma 2007;48:1002–1009.
   Web of Science ®Google Scholar
• Leroy K, Jais JP, Haioun C, et al Gene expression profile associated with survival in patients with diffuse-large B-cell lymphoma treated by chemotherapy and rituximab. Blood 2005;106(Suppl. 1): Abstract 159.
   Google Scholar
• Hoffmann C, Tiemann M, Schrader C, et al AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood 2005;106:1762–1769.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Gaulard P, Leroy K, et al Immunofluorescence in situ hybridization index predicts survival in patients with diffuse-large B cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol 2009;27:5573–5579.
   PubMed Web of Science ®Google Scholar
• Chadburn A, Chen X, Chiu A, et al Neither germinal center (GC) vs non-germinal center (non-GC) phenotype nor FOXP1 expression correlate with outcome in AIDS-associated diffuse-large B-cell lymphoma (DLBCL): study of patients from AIDS Malignancies Consortium Ttrials 010 and 034. Blood 2006;108(Suppl. 1): Abstract 2023.
   Google Scholar
• Chadburn A, Chiu A, Lee JY, et al Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. J Clin Oncol 2009;27:5039–5048.
   PubMed Web of Science ®Google Scholar